BioInvent receives notice of allowance in China for BI-1206 patent
Lund, Sweden – June 24, 2021 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the anti-FcγRllB antibody BI-1206 is granted contingent on payment of the issue fee. This patent allowance is a strategic milestone in BioInvent’s exclusive licensing